Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Published Results
Related Publications
Trial Contact Information
Registry Information

Alternate Title

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Basic Trial Information

Objectives

Primary

1. Compare the progression-free survival and overall survival of patients with newly diagnosed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer treated with carboplatin and paclitaxel with vs without bevacizumab.

Secondary

1. Compare the response rate in patients treated with these regimens.
2. Compare the duration of tumor response in patients treated with these regimens.
3. Compare the biological progression-free interval, as measured by increasing CA 125 levels, in patients treated with these regimens.
4. Compare the safety (e.g., adverse events, laboratory results, and performance status) of these regimens in these patients.
5. Compare the quality of life of patients treated with these regimens.
6. Compare the cost-effectiveness of these regimens in these patients.

Entry Criteria

Disease Characteristics:

• Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer
  • Newly diagnosed disease

• Meets 1 of the following staging criteria:
  • High-risk stage I or IIA disease (grade 3 disease or clear cell carcinoma only)
  • Stage IIB-IV disease (all grades and all histological types)

• Must have undergone initial surgery (e.g., debulking cytoreductive surgery or a biopsy if the patient has stage IV disease) within the past 6 weeks
  • Patients with stage IV disease for which initial surgical debulking was not appropriate are eligible provided the following criteria are met:
    • Stage IV disease diagnosed by histology
    • No planned surgery prior to disease progression, including interval debulking surgery

• Patients with prior early-stage ovarian epithelial or fallopian tube carcinoma treated with surgery alone are eligible at the time of diagnosis of abdominopelvic recurrence provided no further interval cytoreductive therapy is planned prior to disease progression

• Synchronous primary endometrial carcinoma or a past history of primary endometrial carcinoma allowed provided the following criteria are met:
  • Disease ≤ stage IB
  • No more than superficial myometrial invasion
  • No lymphovascular invasion
  • Not poorly differentiated (i.e., no grade 3, papillary serous, or clear cell disease)

• Measurable or nonmeasurable disease

• No ovarian nonepithelial cancer, including malignant mixed Müllerian tumors

• No borderline tumors (e.g., tumors of low malignant potential)

• No history or clinical suspicion of brain metastases or spinal cord compression
  • CT scan or MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases
  • Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression

Prior/Concurrent Therapy:

• See Disease Characteristics
• More than 4 weeks since other prior surgery or open biopsy
• No prior systemic therapy for ovarian cancer (e.g., chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, or hormonal therapy)
• Prior adjuvant chemotherapy allowed for other malignancies (e.g., breast or colorectal carcinoma) if malignancy was diagnosed over 5 years ago with no evidence of subsequent recurrence
• No prior mouse CA 125 antibody
• No prior radiotherapy to the abdomen or pelvis
• More than 10 days since prior and no concurrent chronic use of acetylsalicylic acid (> 325 mg/day)
  • Low-dose (< 325 mg/day) acetylsalicylic acid allowed
• More than 10 days since prior and no concurrent full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes
  • Use of therapy for line patency allowed provided INR < 1.5
• More than 30 days since prior and no other concurrent investigational agent or participation in another clinical trial
• No other concurrent systemic antitumor agents
• No concurrent surgery
• No concurrent maintenance chemotherapy or intraperitoneal chemotherapy (including cytotoxic chemotherapy)

Patient Characteristics:

• ECOG performance status 0-2
• Life expectancy > 12 weeks
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 9 g/dL (can be post-transfusion)
• INR ≤ 1.5
• APTT ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• ALT and AST ≤ 2.5 times ULN
• Creatinine ≤ 2.0 mg/dL
• Proteinuria ≤ 1+ by urine dipstick OR ≤ 1 g by 24-hour urine collection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 6 weeks after completion of study therapy
• No significant traumatic injury within the past 4 weeks
• No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 6 months
• No other malignancies within the past 5 years except for adequately treated carcinoma in situ of the cervix, and/or basal cell skin cancer, and/or early endometrial carcinoma
• No pre-existing sensory or motor neuropathy ≥ grade 2
• No history or evidence of CNS disease (e.g., uncontrolled seizures) by neurological examination unless adequately treated with standard medical therapy
• No history or evidence of thrombotic or hemorrhagic disorders
• No uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg despite antihypertensive therapy)
• No known hypersensitivity to bevacizumab and its excipients, chemotherapy, or Cremophor EL
• No nonhealing wound, ulcer, or bone fracture
  • Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require three weekly wound examinations
• No clinically significant cardiovascular disease, including any of the following:
  • Myocardial infarction or unstable angina within the past 6 months
  • New York Heart Association class II-IV congestive heart failure
  • Poorly controlled cardiac arrhythmia despite medication
    • Rate-controlled atrial fibrillation allowed
  • Peripheral vascular disease ≥ grade 3 (i.e., symptomatic and interfering with activities of daily living requiring repair or revision)
• No evidence of other disease or condition, metabolic dysfunction, physical examination findings, or laboratory findings that would contraindicate the use of an investigational drug or put the patient at high-risk for treatment-related complications

Expected Enrollment

Outcomes

Progression-free survival

Duration of overall survival
Objective response rate
Duration of response
Biological progression-free interval as measured by increasing CA 125 levels
Safety as measured by NCI CTAE version 3.0
Quality of life
Health economics

Outline

This is a multicenter, open-label, randomized, controlled study. Patients are stratified according to FIGO stage (stage I-III with residual disease ≤ 1 cm vs stage I-III with residual disease > 1 cm vs stage IV disease), intended time to start chemotherapy after surgery (≤ 4 weeks vs > 4 weeks), and participating center. Patients are randomized to 1 of 2 treatment arms.

• Arm I (control): Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

• Arm II: Patients receive bevacizumab IV over 30-90 minutes followed by paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab alone every 3 weeks for 12 courses.

Quality of life is assessed at baseline, before every course, every 6 weeks for 1 year, every 3 months until disease progression or for up to 2 years, and then at 3 years. Health economic data is assessed periodically, including days of inpatient hospitalization visits, outpatient visits, and use of anticancer therapies.

After completion of study treatment, patients are followed every 3-6 months for 5 years and then annually thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Perren TJ, Swart AM, Pfisterer J, et al.: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365 (26): 2484-96, 2011.[PUBMED Abstract]

Dhillon S: Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Drugs 72 (7): 917-30, 2012.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Medical Research Council Clinical Trials Unit

Tim Perren, MD, Protocol chair		Ph: 44-113-206-4670 Email: t.j.perren@leeds.ac.uk

Australia
New South Wales
	Liverpool
	Cancer Therapy Centre at Liverpool Hospital
		Contact Person	Ph:  612-9828-5283
	Randwick
	Prince of Wales Private Hospital
		Michael Friedlander, MD, PhD, FRACP	Ph:  61-2-9382-2606
			Email: m.friedlander@unsw.edu.au
	St. Leonards
	Royal North Shore Hospital
		Contact Person	Ph:  612-9926-5052
	Sydney
	Sydney Cancer Centre at Royal Prince Alfred Hospital
		Philip Beale, MD	Ph:  61-2-9515-5895
	Waratah
	Newcastle Mater Misericordiae Hospital
		Antonino Bonaventura, MD	Ph:  61-2-4921-1144
			Email: tony.bonaventura@newcastle.edu.au
	Wentworthville
	Westmead Institute for Cancer Research at Westmead Hospital
		Paul Harnett, MD	Ph:  61-2-9845-6954
Queensland
	Brisbane
	Royal Brisbane and Women's Hospital
		Paul Vasey, MD	Ph:  61-7-3636-8111
	South Brisbane
	Mater Adult Hospital
		Paul Mainwaring, MD, MBBS, FRACP	Ph:  61-738-406-166
			Email: paul.mainwaring@mater.org.au
South Australia
	Adelaide
	Royal Adelaide Hospital Cancer Centre
		Margaret Davy, MD	Ph:  61-8-8222-4816
			Email: margaret.davy@adelaide.edu.au
Tasmania
	Hobart
	Royal Hobart Hospital
		Penelope Blomfield, MD	Ph:  61-3-6222-8049
Victoria
	Box Hill
	Box Hill Hospital
		Contact Person	Ph:  613-9815-0071
	Carlton
	Royal Women's Hospital
		Michael Quinn, MD	Ph:  61-3-9221-5188
			Email: maquinn@unimelb.edu.au
	East Melbourne
	Mercy Hospital for Women
		Danny Rischin, MD	Ph:  61-3-9270-2222
	Frankston
	Frankston Hospital
		Vinod Ganju, MD	Ph:  61-3-9784-7777
			Email: vgc@psehog.com.au
	Wodonga
	Murray Valley Private Hospital and Cancer Treatment Centre
		Contact Person	Ph:  612-6055-3200
Western Australia
	Perth
	Sir Charles Gairdner Hospital - Perth
		Martin Buck, MD	Ph:  61-8-9346-3841
			Email: martin.buck@health.wa.gov.au
France
	Angers
	Centre Paul Papin
		Remy Delva	Ph:  33-49-800-918-507
	Avignon
	Institut Sainte Catherine
		Contact Person	Ph:  33-4-9027-6330 33-4-9027-6283
	Bordeaux
	Clinique Tivoli
		Dominique Jaubert, MD	Ph:  33-556-116-087
			Email: dominique.jaubert@wanadoo.fr
	Institut Bergonie
		Contact Person	Ph:  33-5-5633-3318
	Polyclinique Bordeaux Nord Aquitaine
		Nadine Dohollou, MD	Ph:  33-5-56-43-73-54
	Caen
	Centre Regional Francois Baclesse
		Florence Joly, MD, PhD	Ph:  33-02-31-45-50-17
			Email: f.joly@baclesse.fr
	Clermont-Ferrand
	Centre Jean Perrin
		Contact Person	Ph:  33-4-7327-8141 33-4-7327-8117
	Colmar
	Hopital Louis Pasteur
		Contact Person	Ph:  33-3-8912-4471 33-3-8912-4343
			Email: jeanclaude.barats@ch-colmar.rss.fr
	Grenoble
	CHU de Grenoble - Hopital de la Tronche
		Francois Ringeisen	Ph:  33-4-7676-5537
	Institut Prive de Cancerologie
		David Coeffic, MD	Ph:  33-4-7633-5550
			Email: dcoeffic@club-internet.fr
	Le Chesnay
	Hopital Andre Mignot
		Contact Person	Ph:  33-1-3963-9133 33-1-3963-9408
	Le Mans
	Centre Jean Bernard
		Contact Person	Ph:  33-243-479-494
			Email: h.bourgeois@centre-jean-bernard.org
	Lyon
	Centre Leon Berard
		Isabelle Ray-Coquard, MD	Ph:  33-4-78-78-26-45
	Montpellier
	Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
		Michel Fabbro, MD	Ph:  33-04-67-613-063
			Email: mfabbro@valdorel.fnclcc.fr
	Nancy
	Centre D'Oncologie De Gentilly
		Dominique Spaeth, MD	Ph:  33-3-8393-5005
			Email: oncomed@wanadoo.fr
	Nantes
	Centre Catherine de Sienne
		Alain Lortholary, MD	Ph:  33-40-02-28-272-000
	Nantes-Saint Herblain
	Centre Regional Rene Gauducheau
		Dominique Berton-Rigaud, MD	Ph:  33-2-40-479-959
	Paris
	Hopital Cochin
		Francois Goldwasser, MD, PhD	Ph:  33-158-411-746
			Email: francois.goldwasser@cch.aphp.fr
	Hopital Europeen Georges Pompidou
		Eric Levy, MD	Ph:  33-1-5609-3473
	Hopital Tenon
		Frederic Selle	Ph:  33-1-5601-6021
	Hotel Dieu de Paris
		E. Pujade-Lauraine, MD, PhD	Ph:  33-1-42-34-82-22
			Email: epujade@arcagy.org
	Institut Curie Hopital
		Paul-Henri Cottu	Ph:  33-1-4474-1039
	Pierre Benite
	Centre Hospitalier Lyon Sud
		Veronique Trillet-Lenoir, MD	Ph:  33-78-863-324
			Email: veronique.trillet-lenoir@chu-lyon.fr
	Rouen
	Centre Henri Becquerel
		Cecile Guillemet, MD	Ph:  33-02-32-02-2237
			Email: cecile.guillemet@rouen.fnclcc.fr
	Saint Brieuc
	Clinique Armoricaine De Radiologie
		Anne-Claire Hardy-Bessard, MD	Ph:  33-2-9675-2216
			Email: ac.hardy@clin-armoricaine.fr
	Saint Cloud
	Centre Rene Huguenin
		Contact Person	Ph:  33-1-4711-1515 33-1-4711-1688
	Strasbourg
	Hopital Universitaire Hautepierre
		Jean-Emmanuel Kurtz, MD	Ph:  33-3-88-12-8314
	Tours
	Centre Hospitalier Universitaire Bretonneau de Tours
		Philippe Bougnoux, MD, PhD	Ph:  33-2-4747-8261
	Vandoeuvre-les-Nancy
	Centre Alexis Vautrin
		Contact Person	Ph:  33-3-8359-8365
Germany
	Berlin
	Charite University Hospital - Campus Virchow Klinikum
		Jalid Sehouli, MD	Ph:  49-30-450-564-404
	Evang. Waldkrankenhaus Spandau
		Contact Person	Ph:  49-30-3702-1302
	Bremen
	Klinikum Bremen-Mitte
		Contact Person	Ph:  49-421-497-5361
	Praxis Dres. F.& G. Doering
		Gabriele Doering, MD	Ph:  49-421-498-5068
	Chemnitz
	Klinikum Chemnitz gGmbH
		Contact Person	Ph:  49-371-333-22-191
	Dresden
	Universitatsklinikum Carl Gustav Carus
		Contact Person	Ph:  49-351-458-3508
	Ebersberg
	Kreiskrankenhaus
		Contact Person	Ph:  49-809-282-2501
	Essen
	Elisabeth-Krankenhaus
		Contact Person	Ph:  49-201-897-3501
	Universitaetsklinikum Essen
		Contact Person	Ph:  49-201-723-2245
	Esslingen
	Staedtische Kliniken Esslingen
		Contact Person	Ph:  49-711-310-330-51
	Frankfurt
	Klinikum der J.W. Goethe Universitaet
		Contact Person	Ph:  49-69-6301-6850
	Onkologie Bethanien
		Contact Person	Ph:  49-69-560-05-621
	Staedtische Kliniken Frankfurt am Main - Hoechst
		Volker Moebus, MD	Ph:  49-693-106-3552
			Email: vmoebus@skfh.de
	Freiburg
	Universitaetsfrauenklinik Freiburg
		Contact Person	Ph:  49-761-270-3004
			Email: annette.hasenburg@uniklinik-freiburg.de
	Georgsmarienhuette
	Franziskus Hospital Hardenberg
		Contact Person	Ph:  49-541-502-2531
			Email: gynaekologie@franziskus.com
	Greifswald
	Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet
		Antje-Kristina Belau, MD	Ph:  49-383-486-6511
			Email: belau@mail.uni-greifswald.de
	Halle
	Universitaetsklinikum Halle
		Contact Person	Ph:  49-345-557-4016
	Hannover
	Henriettenstiftung Frauenklinik
		Contact Person	Ph:  49-511-289-3817
	Medizinische Hochschule Hannover
		Contact Person	Ph:  49-511-532-9728
	Karlsruhe
	St. Vincentius - Kliniken
		Contact Person	Ph:  49-721-889-8304
			Email: fraunartz@diak-ka.de
	Kassel
	Klinikum Kassel
		Contact Person	Ph:  49-561-980-3145
	Kiel
	University Hospital Schleswig-Holstein - Kiel Campus
		Contact Person	Ph:  49-431-597-2100
	Lahr
	Kreiskrankenhaus Lahr
		Contact Person	Ph:  49-782-193-2551
			Email: daniel.pfisterer@klinikum-lahr.de
	Leonberg
	Kreiskrankenhaus Leonberg - Frauenklinik
		Harald Wolf	Ph:  49-7152-202-6401
	Lich
	Asklepios Klinik Lich
		Contact Person	Ph:  49-6404-81-385
	Limburg
	St. Vincenz Hospital Limburg
		Contact Person	Ph:  49-643-1292-4451
	Luebeck
	Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
		Contact Person	Ph:  49-451-500-2132
	Lueneburg
	Staedtisches Klinikum Lueneburg
		Contact Person	Ph:  49-4131-77-0
	Magdeburg
	Klinik St. Marienstift Magdeburg
		Contact Person	Ph:  49-391-7262-458
	Mainz
	St. Vincenz und Elisabeth Hospital
		Contact Person	Ph:  49-613-1575-1400
	Marburg
	Universitaetsklinikum Giessen und Marburg GmbH - Marburg
		Contac Person	Ph:  49-6421-28-66-491
	Minden
	Klinikum Minden
		Heinrich Bodenstein, MD	Ph:  49-571-801-4812
			Email: heinrich.bodenstein@klinikum.minden.de
	Munich
	I. Frauenklinik und Hebammenschule der Ludwig-Maximillians Universitaet Muenchen
		Harald Sommer, MD	Ph:  49-89-5160-4313
			Email: harald.sommer@med.uni-muenchen.de
	Klinikum der Universitaet Muenchen - Grosshadern Campus
		Alexander Burges, MD	Ph:  49-897-095-2846
	Klinikum Rechts Der Isar - Technische Universitaet Muenchen
		Barbara Schmalfeldt, MD	Ph:  49-894-1402-433
			Email: barbara.schmalfeldt@lrz.tu-muenchen.de
	Neunkirchen
	Staedtisches Klinikum Neunkirchen gGmbH
		Contact Person	Ph:  49-682-118-2301
	Neuss
	Lukaskrankenhaus Neuss
		Contact Person	Ph:  49-2131-888-2501
	Offenbach
	Klinikum Offenback GmbH
		Contact Person	Ph:  49-69-8405-3850
	Paderborn
	Saint Vincenz-Krankenhaus Paderborn
		Contact Person	Ph:  49-525-186-4122
			Email: w.merinerz@vincenz.edu
	Quedlinburg
	Klinikum Dorothea Christiane Erxleben - Quedlingburg
		Contact Person	Ph:  49-3946-906-1521
	Ravensburg
	Krankenhaus St. Elisabeth - Ravensburg
		Contact Person	Ph:  49-751-87-2389
	Siegen
	St. Marien - Krankenhaus Siegen GMBH
		Contact Person	Ph:  49-271-231-1802
	Sigmaringen
	Kliniken Landkreis Sigmaringen GMBH
		Contact Person	Ph:  49-7571-100-2361
	Stuttgart
	Marienhospital Stuttgart
		Contact Person	Ph:  49-711-648-90
	Robert-Bosch-Krankenhaus
		Walter Aulitzky, MD	Ph:  49-711-8101-3768
			Email: walter.aulitzky@rbk.de
	Ulm
	Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm
		Contact Person	Ph:  49-731-5002-7606
	Wiesbaden
	Dr. Horst-Schmidt-Kliniken
		Andreas du Bois, MD, PhD	Ph:  49-611-433-234
	Witten
	Marien-Hospital Witten
		Contact Person	Ph:  49-2302-173-1323
	Wolfsburg
	Klinikum der Stadt Wolfsburg
		Contact Person	Ph:  49-5361-80-1270
	Wuppertal
	Praxis Fuer Haemotologie Und Internistischer Onkologie
		Werner Fett, MD	Ph:  49-202-449-232
			Email: fett-onkologe@t-online.de
Norway
	Oslo
	Norwegian Radium Hospital
		Gunnar Kristensen, MD, PhD	Ph:  47-2293-4000
			Email: gunnar.kristensen@klinmed.uio.no
United Kingdom
England
	Barnstaple
	North Devon District Hospital
		Mark Napier, MD	Ph:  44-127-132-2414
			Email: mark.napier@ndevon.swest.nhs.uk
	Broomfield
	Broomfield Hospital
		Contact Person	Ph:  44-124-551-4750
	Burton-upon-Trent
	Queen's Hospital
		Mojca Persic	Ph:  44-133-234-7141 ext. 4574
			Email: mojca.persic@derbyhospitals.nhs.uk
	Cambridge
	Addenbrooke's Hospital
		Helena Earl, MBBS, PhD, FRCP	Ph:  44-1223-336-800
	Cheltenham
	Gloucestershire Oncology Centre at Cheltenham General Hospital
		Contact Person	Ph:  44-112-4227-3610
	Exeter
	Royal Devon and Exeter Hospital
		Anne Hong, MD	Ph:  44-39-240-2118
			Email: anne.hong@rdeft.nhs.uk
	Gateshead
	Queen Elizabeth Hospital
		Contact Person	Ph:  44-191-445-2392
	Guildford
	St. Luke's Cancer Centre at Royal Surrey County Hospital
		Contact Person	Ph:  44-148-340-6807
	Hull
	Princess Royal Hospital at Hull and East Yorkshire NHS Trust
		M.J. Lind, MD	Ph:  44-148-267-6701
			Email: m.j.lind@hull.ac.uk
	Ipswich
	Ipswich Hospital
		Jamie Morgan, MBBS, FRCR, MRCP	Ph:  44-147-370-4910
			Email: Jamie.Morgan@ipswichhospital.nhs.uk
	Keighley
	Airedale General Hospital
		S. Michael Crawford, MD	Ph:  44-153-529-2949
			Email: michael.crawford@anhst.nhs.uk
	Leeds
	Leeds Cancer Centre at St. James's University Hospital
		Tim Perren, MD	Ph:  44-113-206-4670
			Email: t.j.perren@leeds.ac.uk
	London
	Guy's Hospital
		Peter Harper, MD	Ph:  44-207-188-4255
			Email: peter.harper@kcl.ac.uk
	Hammersmith Hospital
		Hani Gabra, MD	Ph:  44-208-383-3020
			Email: h.gabra@imperial.ac.uk
	St. George's Hospital
		Fiona Lofts, MD	Ph:  44-20-8725-0231
	University College of London Hospitals
		Jonathan Ledermann, MD	Ph:  44-207-679-9430
			Email: jonathan.ledermann@uclh.nhs.uk
	Maidstone
	Mid Kent Oncology Centre at Maidstone Hospital
		Contact Person	Ph:  44-162-222-5111
	Manchester
	Christie Hospital
		Contact Person	Ph:  44-161-446-8149
	Margate
	Queen Elizabeth The Queen Mother Hospital
		Contact Person	Ph:  44-162-222-5326
	Merseyside
	Clatterbridge Centre for Oncology
		Contact Person	Ph:  44-151-334-1155
	Middlesbrough
	James Cook University Hospital
		Contact Person	Ph:  44-164-285-4736
	Newcastle-Upon-Tyne
	Northern Centre for Cancer Treatment at Newcastle General Hospital
		Contact Person	Ph:  44-191-256-3669
	Northampton
	Northampton General Hospital
		Jill Stewart, MD	Ph:  44-1604-545-238
			Email: Jill.stewart@ngh.nhs.uk
	Northwood
	Mount Vernon Cancer Centre at Mount Vernon Hospital
		Gordon Rustin, MD	Ph:  44-1923-844-389
			Email: grustin@nhs.net
	Norwich
	Norfolk and Norwich University Hospital
		Contact Person	Ph:  44-160-328-7223
	Nottingham
	Nottingham City Hospital
		Stephen Chan, MD	Ph:  44-115-969-1169
			Email: steve.chan@nuh.nhs.uk
	Oxford
	Churchill Hospital
		Contact Person	Ph:  44-186-522-6185
	Plymouth
	Derriford Hospital
		Contact Person	Ph:  44-175-251-7585
	Poole Dorset
	Dorset Cancer Centre
		Contact Person	Ph:  44-120-244-8265
	Portsmouth Hants
	Portsmouth Oncology Centre at Saint Mary's Hospital
		Contact Person	Ph:  44-239-228-6000 ext. 2129
	Sheffield
	Cancer Research Centre at Weston Park Hospital
		Contact Person	Ph:  44-114-226-5000
	Shrewsbury
	Royal Shrewsbury Hospital
		Contact Person	Ph:  44-174-326-1103
	Stoke Mandeville Hospital
		Contact Person	Ph:  44-129-631-5555
	Slough, Berkshire
	Wexham Park Hospital
		Marcia Hall, MD	Ph:  44-175-363-4315
			Email: marcia.hall@nhs.net.uk
	Southampton
	Southampton General Hospital
		Contact Person	Ph:  44-238-077-7222 ext. 8657
	Stafford
	Staffordshire General Hospital
		Contact Person	Ph:  44-178-255-4301
	Sutton
	Royal Marsden - Surrey
		Martin Gore, MD	Ph:  44-208-661-3983
	Swindon
	Great Western Hospital
		Amanda Horne	Ph:  44-117-9360-4336
			Email: amanda.horne@orh.nhs.uk
	Truro, Cornwall
	Royal Cornwall Hospital
		Nigel Bailey, MD	Ph:  44-187-225-8306
			Email: nigel.bailey@nhs.net
	Yeovil - Somerset
	Yeovil District Hospital
		Geoff Sparrow, MD	Ph:  44-193-438-4869
			Email: geoff@stalbridgesurgery.co.uk
Northern Ireland
	Belfast
	Centre for Cancer Research and Cell Biology at Queen's University Belfast
		Contact Person	Ph:  44-289-026-2264
Scotland
	Aberdeen
	Aberdeen Royal Infirmary
		Andrew Hutcheon, MD	Ph:  44-122-489-2997
			Email: andrew.hutcheon@arh.grampian.scot.nhs.uk
	Dundee
	Ninewells Hospital
		Elaine Rankin, MD	Ph:  44-1382-425-543
			Email: e.m.rankin@dundee.ac.uk
	Edinburgh
	Edinburgh Cancer Centre at Western General Hospital
		Contact Person	Ph:  44-131-777-3555
Wales
	Bangor
	Ysbyty Gwynedd
		Nick Stuart, MD	Ph:  44-124-3841-50
			Email: nick.stuart@nww-tr.wales.nus.uk
	Swansea
	South West Wales Cancer Institute
		Gianfilippo Bertelli, MD, FRCPE	Ph:  44-179-228-5826
			Email: gianfilippo.bertelli@swansea-tr.wales.nhs.uk

Registry Information
Official Title		ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer
Trial Start Date		2006-04-09
Registered in ClinicalTrials.gov		NCT00483782
Date Submitted to PDQ		2007-05-03
Information Last Verified		2012-04-30

Back to Top